Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luis J Schwarz

Showing results (1-10 of 18) with videos related to

Pageof 2
Sort By:
Molecular & Cellular Oncology|September 22, 2016
Maybe we don't know JAK?Luis J Schwarz, Justin M Balko
Clinical Medicine Insights. Oncology|August 27, 2019
Patterns of Mutation Enrichment in Metastatic Triple-Negative Breast CancerCésar H Saravia, Claudio Flores, Luis J Schwarz, et al.
Critical Reviews in Oncology/Hematology|February 18, 2019
Helicobacter pylori: History and facts in PeruIndira Tirado-Hurtado, Cristian Carlos, Luciana Lancho, et al.
Cancer Research|August 23, 2013
Activation of MAPK pathways due to DUSP4 loss promotes cancer stem cell-like phenotypes in basal-like breast cancerJustin M Balko, Luis J Schwarz, Neil E Bhola, et al.
Ecancermedicalscience|February 23, 2019
Precision medicine for locally advanced breast cancer: frontiers and challenges in Latin AmericaJoseph A Pinto, César H Saravia, Claudio Flores, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2018
Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER<sup>+</sup>/HER2<sup>+</sup> Breast Cancers: Implications to the ExteNET TrialDhivya R Sudhan, Luis J Schwarz, Angel Guerrero-Zotano, et al.
The Journal of Clinical Investigation|November 18, 2014
LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancerLuis J Schwarz, Emily M Fox, Justin M Balko, et al.
Journal of the National Cancer Institute|October 24, 2017
An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand OverexpressionLuis J Schwarz, Katherine E Hutchinson, Brent N Rexer, et al.
Frontiers in Oncology|November 5, 2021
Influence of Sex in the Molecular Characteristics and Outcomes of Malignant TumorsJhajaira M Araujo, Gina Rosas, Carolina Belmar-López, et al.
Cell Metabolism|October 6, 2017
MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative PhosphorylationKyung-Min Lee, Jennifer M Giltnane, Justin M Balko, et al.
Pageof 2

Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Molecular & Cellular Oncology|September 22, 2016
Maybe we don't know JAK?Luis J Schwarz, Justin M Balko
Clinical Medicine Insights. Oncology|August 27, 2019
Patterns of Mutation Enrichment in Metastatic Triple-Negative Breast CancerCésar H Saravia, Claudio Flores, Luis J Schwarz, et al.
Critical Reviews in Oncology/Hematology|February 18, 2019
Helicobacter pylori: History and facts in PeruIndira Tirado-Hurtado, Cristian Carlos, Luciana Lancho, et al.
Cancer Research|August 23, 2013
Activation of MAPK pathways due to DUSP4 loss promotes cancer stem cell-like phenotypes in basal-like breast cancerJustin M Balko, Luis J Schwarz, Neil E Bhola, et al.
Ecancermedicalscience|February 23, 2019
Precision medicine for locally advanced breast cancer: frontiers and challenges in Latin AmericaJoseph A Pinto, César H Saravia, Claudio Flores, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2018
Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER<sup>+</sup>/HER2<sup>+</sup> Breast Cancers: Implications to the ExteNET TrialDhivya R Sudhan, Luis J Schwarz, Angel Guerrero-Zotano, et al.
The Journal of Clinical Investigation|November 18, 2014
LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancerLuis J Schwarz, Emily M Fox, Justin M Balko, et al.
Journal of the National Cancer Institute|October 24, 2017
An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand OverexpressionLuis J Schwarz, Katherine E Hutchinson, Brent N Rexer, et al.
Frontiers in Oncology|November 5, 2021
Influence of Sex in the Molecular Characteristics and Outcomes of Malignant TumorsJhajaira M Araujo, Gina Rosas, Carolina Belmar-López, et al.
Cell Metabolism|October 6, 2017
MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative PhosphorylationKyung-Min Lee, Jennifer M Giltnane, Justin M Balko, et al.
Pageof 2